Clinical trials: II-IIIB Stages
Stage II-IIIB Non-small Cell Lung Carcinoma
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.
- Trial name
- TARGET (NCT05526755)
- Testing
- Osimertinib 80 mg/40 mg
- Where
- 56 sites in United States, Hong Kong and 9 more
- Volunteers
- 188 people
- Sponsor
- AstraZeneca